PTEN and cancer: Moses et al. used CRISPR/Cas9 along with trans-activator VP64p65-Rta (VPR) to activate the expression of PTEN in cancer cells, demonstrated that the activation of PTEN can significantly inhibit the downstream carcinogenic pathway (Moses et al., 2019).